Whether you're sourcing suppliers or finding providers, start your journey with confidence today.
Cerebrolysin (Porcine Brain-Derived Peptide Preparation)
Also known as: FPF-1070, Brain-Derived Neurotrophic Peptides
Confidence
Updated 2026-03-18
Cerebrolysin is a porcine brain-derived peptide preparation containing low-molecular-weight neuropeptides and free amino acids that mimic endogenous neurotrophic factors. It is approved in over 50 countries (not the US) for stroke recovery, traumatic brain injury, and dementia. It is one of the most widely prescribed neuroprotective agents globally, with a substantial clinical trial database.
Class
Neuroprotective Peptide Complex
Routes
Intravenous, Intramuscular
Half-Life
Not applicable (complex mixture). Biological effects persist hours to days after administration.
Cerebrolysin contains peptide fragments that mimic the activity of BDNF, NGF, CNTF, and GDNF (endogenous neurotrophins). It promotes neuronal survival, stimulates neurogenesis and synaptogenesis, enhances neuroplasticity, reduces excitotoxicity (glutamate regulation), decreases amyloid-beta aggregation (Alzheimer's), and protects against oxidative stress. It crosses the blood-brain barrier and acts on multiple neurotrophic signaling cascades simultaneously.
Half-Life
Not applicable (complex mixture). Biological effects persist hours to days after administration.
Bioavailability
IV/IM: high (direct systemic delivery). Oral: not available (peptides degraded in GI tract).
Approved internationally: Ischemic stroke recovery, traumatic brain injury, Alzheimer's dementia, vascular dementia. Research: Parkinson's disease, autism spectrum disorder (limited studies).
Extensive clinical trial database. CASTA trial (stroke, n=1070) and CERE-SIGHT trial (Alzheimer's, n=350+) are among the largest. Cochrane review of Cerebrolysin for acute ischemic stroke found some evidence of benefit but recommended further high-quality trials. Meta-analyses suggest improvement in cognitive scores for dementia. A 2020 Lancet Neurology commentary raised methodological concerns about some trials. Overall evidence is moderate — better than many neuroprotective agents but not at the standard Western regulatory bodies typically require.
Human Studies
80
Animal Studies
150
Generally well-tolerated. Common: dizziness, headache, injection site reactions, agitation (rare). Rare: seizures (especially in epilepsy-prone patients), allergic reactions. Contraindicated in status epilepticus and severe renal impairment. Risk of anaphylaxis in patients with porcine protein allergy.
Approved in 50+ countries. Not FDA-approved — no US marketing authorization sought. Available through international pharmacies or medical tourism. Some US clinics prescribe through compounding or international sourcing.
Drug Interactions: No major interactions known. Caution with antidepressants (theoretical additive serotonergic effect). Not to be mixed with lipid-containing infusions. Monitoring: Neurological assessment, cognitive testing (MMSE, ADAS-Cog), seizure history. Research Gaps: Western regulatory-standard Phase III trials needed. Heterogeneity of the peptide mixture makes standardization complex. Exact active components not fully characterized.
Intravenous infusion
Common Range
10–30 mL/day (stroke/TBI) or 10 mL/day (dementia) diluted in 100–250 mL normal saline
Timing
Infused over 15–60 minutes
Frequency
Daily for 10–21 days (acute stroke) or 5 days/week for 4 weeks (dementia)
Cycling
Acute: 10–21 day courses. Chronic: repeat courses at 3–6 month intervals.
Storage
Room temperature. Do not freeze.
Important Note
NOT FDA-approved. Approved in 50+ countries. Each mL contains 215.2 mg of peptide preparation. Must be administered under medical supervision.
Connect with a verified provider offering Cerebrolysin therapy near you.
Nootropic / Neuroprotective Peptide
Semax is a synthetic heptapeptide analog of ACTH(4-10) developed at the Institute of Molecular Genetics in Russia. It is approved in Russia and several CIS countries as a nootropic and neuroprotective agent for stroke recovery, cognitive enhancement, and optic nerve disease. Unlike full-length ACTH, it has no corticosteroid-stimulating activity.
Nootropic / Anxiolytic Peptide
Selank is a synthetic heptapeptide derived from the endogenous immunomodulatory peptide tuftsin, with an added Pro-Gly-Pro sequence for stability. Developed at the Institute of Molecular Genetics (Russian Academy of Sciences), it is approved in Russia as an anxiolytic and nootropic. It exhibits both anxiolytic and cognitive-enhancing properties without sedation or addiction potential.
Nootropic / Cognitive Enhancer
Dihexa is a small peptide-derived compound developed at Washington State University that acts as a potent hepatocyte growth factor (HGF) receptor (c-Met) agonist. In preclinical studies, it demonstrated cognitive-enhancing effects up to 10 million times more potent than BDNF in promoting synaptic connectivity. It is one of the most discussed compounds in nootropic communities, though human data is essentially absent.
Disclaimer: This content is for educational and informational purposes only and does not constitute medical advice. Always consult with a licensed healthcare provider before starting, stopping, or modifying any peptide therapy. PeptideSupplierMatch does not prescribe, sell, or distribute peptides.
Whether you're sourcing peptides for your business or looking for providers near you, we can help.